1. China Stocks

  2. •

    Retail trade

  3. •

    Drugstore chains
Yixintang Pharmaceutical Group Co., Ltd. Class A

Yixintang Pharmaceutical Group Co., Ltd. Class A

SSZSE:002727
12.69
CNY
-0.28
(-2.16%)
0.60EPS
16.21P/E
5.62BMarket Cap
Oct 29Next Earn
Yixintang Pharmaceutical Group Co., Ltd. Class A
SZSE:002727
(Shenzhen Stock Exchange)

Recent

price

12.69

P/E

ratio

16.21

div

yld

4.15%

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
CNY
4.99
5.68
7.28
9.09
9.72
10.22
12
14.89
16.16
18.46
22.11
24.72
29.38
29.12
30.39
30.08
29.38
Revenue per Share
0.28
0.35
0.47
0.62
0.65
0.67
0.68
0.81
0.92
1.06
1.38
1.56
1.7
0.92
0.19
0.46
0.59
Basic EPS, GAAP
- -
0.01
0.14
0.21
0.04
-0.02
0.09
0.48
0.84
1.37
1.32
2.37
3.62
3.12
2.47
2.35
- -
Free Cash Flow per Basic Share
0.1
0.03
0.03
0.03
0.02
0.32
0.26
0.32
0.37
0.35
0.31
0.31
0.32
0.44
0.44
0.53
0.53
Dividend per Share
1.25
1.6
2.07
2.68
4
4.38
4.8
6.51
7.13
8.09
9.68
11.03
12.46
13
12.79
12.47
12.71
Book Value per Share
1.22
1.56
2.03
2.64
3.94
3.3
3.1
4.5
5.09
6.06
7.63
8.51
9.84
9.92
9.03
8.64
8.86
Tangible Book Value per Share
371
390
390
390
456
521
521
521
568
568
572
590
593
597
592
576
577
Basic Weighted Avg Shares
1,850
2,219
2,842
3,547
4,428
5,321
6,249
7,751
9,176
10,479
12,656
14,587
17,432
17,380
18,000
17,336
16,950
Sales/Revenue/Turnover
7.05
7.58
7.63
8.08
9.12
8.25
7.52
8.31
8.66
7.68
7.7
8.91
9.25
6.07
3.15
4.3
4.62
Operating Margin (%)
- -
19
22
25
37
52
67
73
74
73
80
1,088
1,001
1,158
1,258
1,252
- -
Depreciation Expense
103
135
183
241
297
346
353
423
521
604
790
922
1,010
549
114
263
341
Net Income, GAAP
19.4
15.92
11.16
11.33
14.56
11.2
13.63
22.7
24.85
19.46
17.53
16.35
17.98
20.23
46.8
33.17
31.66
Effective Tax Rate (%)
5.56
6.07
6.42
6.79
6.71
6.51
5.65
5.45
5.68
5.76
6.24
6.32
5.79
3.16
0.63
1.52
2.01
Profit Margin (%)
315
379
481
606
1,543
1,106
1,683
2,354
1,774
2,759
2,178
1,809
2,581
2,693
2,080
2,082
2,335
Working Capital
3
3
- -
- -
- -
- -
794
796
- -
483
1,795
1,764
1,759
1,552
1,531
1,266
1,012
LT Debt
497
629
811
1,050
2,083
2,280
2,498
3,694
4,055
4,596
5,780
6,673
7,528
7,877
7,653
7,457
7,608
Total Equity
17.95
17.07
19.59
20.74
17.39
13.36
10.81
9.75
10.55
11.64
11.13
9.86
9.95
5.73
1.35
2.72
3.38
Return on Invested Capital (%)
20.41
19.24
21.64
22.69
18.28
14.61
12.44
11.85
11.8
12.7
12.12
11.63
11.16
6.01
1.82
3.31
4.02
Return on Capital (%)
27.54
24.2
25.53
25.99
19
15.88
14.8
13.66
13.46
13.97
15.25
14.93
14.42
7.24
1.5
3.56
4.57
Return on Common Equity (%)

Capital Structure

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
1,370
1,359
1,395
LT Borrowings
- -
- -
9
LT Finance Leases
1,266
1,169
1,003
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
586
586
586
Market Capitalization
7,531
7,425
5,616

Working Capital

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
8,947
9,226
8,993
Cash, Cash Equivalents & STI
3,062
3,297
3,466
Accounts Receivable, Net
1,362
1,446
1,309
Inventories
3,673
3,673
3,457
Total Current Liabilities
6,864
6,861
6,658
Payables & Accruals
- -
- -
- -
ST Debt
1,370
1,359
1,395
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
13.38%
5.5%
-2.56%
Free Cash Flow
1.55%
19.43%
-7.55%
Net Income, GAAP
12.39%
6.44%
130.8%
Sales/Revenue/Turnover
12.92%
6.87%
-3.69%
Total Cash Common Dividend
7.62%
12.45%
17.02%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
5,100
4,206
4,284
4,411
18,000
2025
4,767
4,148
- -
4,335
17,336
2026
4,434
4,034
- -
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.41
0.07
0.02
-0.3
0.19
2025
0.27
0.16
- -
-0.01
0.46
2026
0.3
0.14
- -
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.01
0.41
0.01
0.01
0.44
2025
0.01
0.31
- -
- -
0.53
2026
0.01
0.21
- -
- -
- -
Similar Companies
CVS Health Corporation (NYSE:CVS)
MatsukiyoCocokara & Co. (TSE:3088)
TSURUHA Holdings, Inc. (TSE:3391)
Guardian Pharmacy Services, Inc. (NYSE:GRDN)
MedPlus Health Services Ltd. (NSE:MEDPLUS)
Raia Drogasil S.A. (B3:RADL3)
Business
Yixintang Pharmaceutical Group Co., Ltd. engages primarily in pharmaceutical retail chain operations and pharmaceutical distribution across China. The company offers traditional Chinese medicines, western medicines, medical equipment, birth control products, disinfection products, healthcare products, and medical devices through an extensive network of chain drugstores under brands including Hongxiang, Shanshang, Huipin, Bendian, and Hanzun; it also produces proprietary pharmaceuticals and provides wholesale distribution services. Founded in 2000 and headquartered in Kunming, Yunnan province, Yixintang operates predominantly in southwest China with expansions into South China, Northern China, Central China, and East China regions, employing over 36,000 people and serving urban and rural markets as a key player in the domestic healthcare supply chain. Recent developments include the completion of an acquisition of assets and inventories from 10 stores of Yiliang Yijun Pharmaceutical Co., Ltd. for CNY 8.40 million in February 2024; authorization and execution of multiple share buyback plans, such as one in February 2025 for up to CNY 150 million and another closed in November 2024; and funding injections to subsidiaries like Yixintang Pharmaceutical, Yixin Convenience Store Chain, Guizhou Hongxiang Yixintang, Sichuan Yixintang, Guangxi Hongxiang Yixintang, and Chongqing Hongxiang Yixintang totaling over CNY 300 million in 2024-2025 to support operational expansions.